标题:
原发中枢神经系统淋巴瘤Primary Central Nervous System Lymphoma
作者:
黄德沛, 黄韵红
关键字:
中枢神经系统淋巴瘤, 临床特征, 预后, 治疗, 大剂量甲氨蝶呤化疗Central Nervous System Lymphoma, Clinical Features, Prognosis, Treatment, High-Dose
Methotrexate Chemotherapy
期刊名称:
《Advances in Clinical Medicine》, Vol.5 No.3, 2015-07-16
摘要:
目的：分析11例中枢淋巴瘤的临床特点及预后。方法：收集我院2007年至2013年11例原发性中枢神经系统淋巴瘤患者的临床资料进行回顾性分析，并参考近年来国内外文献，对原发中枢神经系统淋巴瘤的临床特征及其疗效预后进行探讨。结果：11例患者经放化疗结合治疗后并随访暂无复发，3例患者术后放化疗治疗后复发在化疗并随访中，患者恢复良好。11例患者5年总生存率“OS”为50%。结论：原发中枢神经系统淋巴瘤早期临床诊断困难，明确病理类型后，大剂量甲氨蝶呤化疗是其主要治疗方法，并同步放化疗的综合治疗措施,能提高患者生存质量，延长生存期。
Purpose: Study of clinical features and prognosis of 11 CNS (central nervous system) lymphoma cases. Methods: Discuss on the clinical features and prognosis of the CNS lymphoma by analyzing clinical files of the primary CNS lymphoma patients in our hospital from 2007 to 2013 with recent domestic and international studies for reference. Results: 11 patients temporarily show no relapse of CNS lymphoma after radiotherapies, chemotherapies and follow-up clinic visits. 3 patients relapse after radical and chemical therapies but recover well after follow-up visits in hospital. The general OS survival rate of the 11 cases is 50%. Conclusion: It is difficult to diagnose clinically of the primary CNS lymphoma at its early stage. Large dose of using methotrexate is the main treating method after diagnosis of its pathological mechanism. With synchronous radiotherapy and chemotherapy, the living quality and life span of patients would be enhanced accordingly.